Innovent Bio's Key Drug Price Drops by 25%, Confirms Participation in Medical Insurance NegotiationsOn May 6, the Jiangsu Provincial Public Resources Trading Center showed that the price of Innovent Bio's Fuzelase tablet has dropped from 24,900 yuan per bottle to 18,600 yuan, a decrease of 25.3%.On May 7, Innovent Bio informed the media that the drug Fuzelase Tablet would participate in this year's adjustment of the National Medical Insurance Drug List in China.Fluzoparib tablets were approved in August last year, jointly developed and commercialized by Innovent Bio and JF Pharma, and are the first KRAS G12C inhibitor in China.
But the competitive pressure on Fluorouracil Tablets is not small. In addition to Innovent Bio, there is also the approval received in November of last year.Gesorex tablets from Innovent Bio/Zhengda Tianqing; additionally, Gorase tablets, which are about to be approved, come from Alis/Jacobi. The three parties will jointly compete in the field of second-line KRAS G12C gene mutation non-small cell lung cancer.Ailis has clearly stated that it will fully promote the approval and market launch of Geleise tablets as soon as possible, and strive to participate in this year's medical insurance negotiation.RemeGen's "Disitamab Vedotin" Approved for New Indication! Treatment for Breast CancerOn May 9, the approval information published on the official website of China's National Medical Products Administration (NMPA) showed that a new indication application for RemeGen's HER2-targeted antibody-drug conjugate (ADC), Disitamab Vedotin for Injection, has been approved. This approval applies to patients with HER2-positive (HER2 immunohistochemistry test result of 3+ or FISH+) advanced breast cancer with liver metastases who have previously received trastuzumab or its biosimilars and taxane-based therapies. This is the third indication for this product to be approved in China.The Fourth Indication! Hansoh Pharma's "Almonertinib" Approved for NSCLC Adjuvant TreatmentOn May 9, the NMPA website announced that Hansoh Pharma's "Amethistatin Mesylate Tablets" (Almera®) had been approved for a new indication, used as adjuvant therapy post-tumor resection in adult patients with non-small cell lung cancer (NSCLC) who are positive for epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutations.Almonertinib is the first domestically produced third-generation EGFR-TKI in China, which was approved for marketing as early as March 2020 and entered the medical insurance catalog through negotiation in the same year. This approval marks the fourth indication for almonertinib since its market launch.AstraZeneca Exits Neuroscience FieldAstraZeneca's Q1 2025 financial report shows that the company has terminated the development of multiple neuroscience projects, including MEDI1814, which was being co-developed with Eli Lilly for the treatment of Alzheimer’s disease, MEDI0618, a monoclonal antibody for migraine in Phase 2 clinical trials, and MEDI7352, a bispecific antibody for treating diabetic neuropathic pain. With this, the company's neuroscience pipeline has been completely cleared.AstraZeneca's Financial Performance in Q1 2025: Total Revenue Reaches $13.588 Billion, with Product Revenue at $13.51 Billion; Oncology Business Accounts for 42% Core Share at $5.643 Billion. Diabetes Drug Farxiga Grows 15% Year-over-Year to $2.058 Billion, Becoming the Core Driver of Revenue Growth.Compared with the strong performance of the above-mentioned leading businesses, its neuroscience pipeline contributes relatively less. Soliris (eculizumab), used for treating the rare disease Neuromyelitis Optica Spectrum Disorder (one of the approved indications for this drug), saw a 40% drop in revenue to $444 million in the first quarter of 2025, accounting for only 3% of the company's total revenue.RMB 1.345 Billion! Minghui Pharmaceuticals and Qilu Pharmaceuticals Reach B7-H3 ADC Licensing CollaborationOn May 9, Minghui Pharmaceuticals announced that it had entered into an exclusive license and collaboration agreement with Qilu Pharmaceuticals to develop, manufacture, and commercialize its B7-H3 ADC (MHB088C) in Greater China (including mainland China, Hong Kong, Macao, and Taiwan).According to the agreement, Qilu Pharmaceutical will obtain exclusive rights to MHB088C in the aforementioned regions. Minghui Pharmaceuticals is expected to receive total payments of up to 1.345 billion RMB, including an upfront payment and near-term milestone payments totaling 280 million RMB, as well as development, regulatory, and sales milestone payments amounting to 1.065 billion RMB, along with net product sales royalties in the double-digit percentage range. Minghui Pharmaceuticals will retain global rights to MHB088C outside of Greater China and continue to advance development efforts in those regions.MHB088C is an innovative B7-H3-targeted antibody-drug conjugate developed by Minghui Pharmaceuticals using its proprietary SuperTopoi™ ADC platform. It is renowned for its potent anti-tumor activity and excellent safety profile, significantly broadening the therapeutic window.Trump Pushes Bio-Manufacturing Executive Order AgainOn May 5, 2025, Eastern Time, Trump signed an executive order requiring the U.S. Food and Drug Administration (FDA) to reduce regulatory barriers for domestic pharmaceutical manufacturers in order to promote the restoration of a robust manufacturing base for prescription drugs in the United States, including the key ingredients and materials needed for manufacturing prescription drugs.At the same time, this executive order also directs the FDA to increase fees and inspections for foreign manufacturing plants, strengthen enforcement of reporting requirements for active pharmaceutical ingredient sources by foreign drug manufacturers, and consider publicly disclosing the list of facilities that do not comply with regulations.The White House pointed out that the background of this executive order is that there are still key obstacles and gaps in establishing a resilient and affordable pharmaceutical supply chain for American patients—new facilities must navigate various requirements at the federal, state, and local levels, including building standards, zoning restrictions, environmental protocols, etc., which undermine the certainty needed to attract investment in large manufacturing projects.It is estimated that building new manufacturing capacity under a series of requirements could take up to 5 to 10 years.The White House stated that this move demonstrates Trump's commitment to his "America First" promise, ensuring that the FDA prioritizes domestically manufactured facilities over foreign ones. Building on actions taken during Trump's first term, this executive order aims to bring the production of essential medicines back to the U.S. and reduce reliance on foreign manufacturers.Since announcing its plan to pursue a secondary listing in Hong Kong at the end of last year, Hengrui's landing on the Hong Kong Stock Exchange has officially entered the countdown. On the last day of the May Day holiday, information disclosed on the Hong Kong Stock Exchange's official website showed that Hengrui Medicine has passed the hearing, with the latter also occurring on May 5.Month6Updated the data set after the hearing in the morning.
It is reported that Hengrui may be able to do so at the earliest5Officially listed on the Hong Kong Stock Exchange in the month, becoming the...20China hasA+HAn innovative drug company with a dual listing structure, thereby opening up overseas financing channels,Accelerate business globalization, etc.
This trip to Hong KongIPO, Hengrui expects to raise funds20Hundreds of millions of dollars will be planned for use in clinical research and development of innovative drugs and drugs in the pipeline, developing innovative drugs, potential global acquisitions and collaborations; building new production and R&D facilities in China and overseas markets, and expanding or upgrading existing production facilities in China, etc.5Month7Recently, BeiGene, a leading innovator in China's pharmaceutical industry, announced that the company has benefited from the sales growth of core products such as zanubrutinib.2025Profit turned from loss to profit in the first quarter of the year, and under the U.S. Generally Accepted Accounting Principles (GAAP), achieving quarterly profitability for the first time and successfully reaching the turning point.
"Flexing muscles" is not unique to BeiGene. Earlier, Innovent Bio, Junshi Biosciences, and others also reported sales growth of their core products in the first quarter report this year, further narrowing the companies' profit losses.
As commercialized products continue to increase in volume, more and more Chinese innovative drug companies are about to enter a new development cycle driven by profitability.
◆ New Healthcare solicits contributions extensively. The content can cover topics related to the pharmaceutical industry, such as pharmaceutical policies, R&D trends, and the capital market. Please send your submissions to (zhongsiqian@sinohealth.cn) and include your contact information.
◆ For business cooperation/reprint authorization, please contact 15814031370 (same number for WeChat).
Click below to followXinkangjie, Get MoreHotspot DistributionAnalysis/Industry ResearchReport/Blue Paper。1. Some articles on "New Health Frontier" are reproduced from the Internet with the purpose of conveying more information, without implying endorsement or verification of their viewpoints or authenticity. If you have any questions about the content, please contact our company in a timely manner.
2. "Xinkangjie" is committed to providing reasonable, accurate, and complete information, but does not guarantee the reasonableness, accuracy, or completeness of the information, and assumes no responsibility for any loss or damage caused by unreasonable, inaccurate, or omitted information.
3. All information on "New Health Frontier" is for reference only and should not be used as the basis for any commercial transactions or medical services. If there are any discrepancies resulting from the independent use of the content on "New Health Frontier," our company assumes no responsibility, including but not limited to legal liability or compensation.4. For issues not covered in this statement, please refer to relevant national laws and regulations. In case of any conflict between this statement and national laws and regulations, the latter shall prevail.
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)